Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease

Movement Disorders

Volumn 25, Issue 10, 2010, Pages 1379-1390

  Johnston, Tom H ^a   Van Der Meij, Anne ^b   Brotchie, Jonathan M ^a   Fox, Susan H ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Dyskinesia; Famotidine; Histamine; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOREA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG MEGADOSE; DYSKINESIA; DYSTONIA; FEMALE; LEVODOPA INDUCED DYSKINESIA; LOW DRUG DOSE; MACACA; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; AKATHISIA; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; INTOXICATION; MACACA FASCICULARIS; TIME;

AKATHISIA, DRUG-INDUCED; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; LEVODOPA; MACACA FASCICULARIS; MALE; MPTP POISONING; TIME FACTORS;

EID: 77954978424     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23069     Document Type: Article

References (47)

1. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-2417.
2. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
3. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update:pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
4. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Sub-committee of the American Academy of Neurology. Neurology 2006;66:983-995.
5. Anichtchik OV, Rinne JO, Kalimo H, Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol 2000;163:20-30.
6. Rinne JO, Anichtchik OV, Eriksson KS, et al. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J Neurochem 2002;81:954-960.
7. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol 2006;147 (Suppl 1):S127-S135.
8. Vizuete ML, Traiffort E, Bouthenet ML, et al. Detailed mapping of the histamine H2 receptor and its gene transcripts in guineapig brain. Neuroscience 1997;80:321-343.
9. Anichtchik OV, Peitsaro N, Rinne JO, et al. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis 2001;8:707-716.
10. Martinez-Mir MI, Pollard H, Moreau J, et al. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 1993; 15:209-220.
11. Prast H, Tran MH, Fischer H, et al. Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:558-564.
12. Gomez-Ramirez J, Johnston TH, Visanji NP, et al. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006;21:839-846.
13. Schunack W. Pharmacology of H2-receptor antagonists: an overview. J Int Med Res 1989;17 (Suppl 1):9A-16A.
14. Visanji NP, Fox SH, Johnston TH, et al. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther 2009;328:276-283.
15. Visanji NP, Fox SH, Johnston T, et al. Dopamine D(3) receptor stimulation underlies the development of L-dopa-induced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis 2009;35:184-192.
16. Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004;485:159-164.
17. Gregoire L, Samadi P, Graham J, et al. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009;15:445-452.
18. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden D, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, Vol.II. New Jersey: Macmillan Healthcare Information; 1987. p 153-163, 293-304.
19. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
20. Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 2008;60:57-66.
21. Tahara H, Kusuhara H, Chida M, et al. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 2006;316:1187-1194.
22. Merck-Frosst. Pepcid (famotidine) tablet product monograph. Kirkland, Quebec: Merck-Frosst; 2007. p 1-11.
23. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 1991;20:218-236.
24. Rosse RB, Kendrick K, Fay-McCarthy M, et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 1996;19:341-348.
25. Molinari SP, Kaminski R, Di Rocco A, Yahr MD. The use of famotidine in the treatment of Parkinson's disease: a pilot study. J Neural Transm Park Dis Dement Sect 1995;9:243-247.
26. Hung SW, Adeli GW, Arenovich T, et al. Patient perception of dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry (in press).
27. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
28. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802.
29. Hill MP, Ravenscroft P, Bezard E, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004;310: 386-394.
30. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:873-878.
31. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-85.
32. Anichtchik OV, Huotari M, Peitsaro N, et al. Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Eur J Neurosci 2000;12:3823-3832.
33. Ryu JH, Yanai K, Watanabe T. Marked increase in histamine H3 receptors in the striatum and substantia nigra after 6-hydroxydopamine-induced denervation of dopaminergic neurons: an autoradiographic study. Neurosci Lett 1994;178:19-22.
34. Chen K, Wang JJ, Yung WH, et al. Excitatory effect of histamine on neuronal activity of rat globus pallidus by activation of H2 receptors in vitro. Neurosci Res 2005;53:288-297.
35. Zhou FW, Xu JJ, Zhao Y et al. Opposite functions of histamine H1 and H2 receptors and H3 receptor in substantia nigra pars reticulata. J Neurophysiol 2006;96:1581-1591.
36. Sittig N, Davidowa H. Histamine reduces firing and bursting of anterior and intralaminar thalamic neurons and activates striatal cells in anesthetized rats. Behav Brain Res 2001;124:137-143.
37. Prast H, Tran MH, Lamberti C, et al. Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H1 and H2 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;360:552-557.
38. Nomoto M, Thompson PD, Sheehy MP, et al. Anticholinergic-induced chorea in the treatment of focal dystonia. Mov Disord 1987;2:53-56.
39. Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 2007;30:545-553.
40. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005;112:359-391.
41. Davis BJ, Aul EA, Granner MA, Rodnitzky RL. Ranitidine-induced cranial dystonia. Clin Neuropharmacol 1994;17:489-491.
42. Kapur V, Barber KR, Peddireddy R. Ranitidine-induced acute dystonia. Am J Emerg Med 1999;17:258-260.
43. Peiris RS, Peckler BF. Cimetidine-induced dystonic reaction. J Emerg Med 2001;21:27-29.
44. Augood SJ, Hollingsworth Z, Albers DS, et al. Dopamine transmission in DYT1 dystonia. Adv Neurol 2004;94:53-60.
45. Walker RH, Shashidharan P. Developments in the molecular biology of DYT1 dystonia. Mov Disord 2003;18:1102-1107.
46. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5:864-872.
47. Schlicker E, Malinowska B, Kathmann M, Gothert M. Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 1994;8:128-137.